{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T02:15:25Z","timestamp":1775960125106,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We describe the case of a 24-year-old male patient with\u00a0multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15\u00a0months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15\u00a0months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case\u00a0suggests considering this potential association.<\/jats:p>","DOI":"10.1007\/s40620-022-01504-9","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T19:13:34Z","timestamp":1669144414000},"page":"659-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-5925","authenticated-orcid":false,"given":"Anne-Sofie","family":"Greve","sequence":"first","affiliation":[{"name":"Department of Medicine, Viborg Regional Hospital, Viborg, Denmark 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivagini","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Neurology, Viborg Regional Hospital, Viborg, Denmark 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Krag","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aarhus University Hospital, Aarhus, Denmark 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else","family":"Randers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Viborg Regional Hospital, Viborg, Denmark 1"},{"name":"Research Unit of Multimorbidity, Viborg Regional Hospital, Viborg, Denmark 4"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"4","key":"2026012001321329000_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2215\/CJN.07311009 20203164","article-title":"Treatment with IFN-\u03b1, -\u03b2, or -\u03b3 is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2026012001321329000_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x 14717935","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"2026012001321329000_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1681\/ASN.2009040450 19917783","article-title":"Development of focal segmental glomerulosclerosis after anabolic steroid abuse","volume":"21","author":"Herlitz","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2026012001321329000_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-019-01135-8 31098896","article-title":"Teriflunomide: a review in relapsing-remitting multiple sclerosis","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"2026012001321329000_CR5"},{"key":"2026012001321329000_CR6","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.msard.2020.102506 32979731","article-title":"Teriflunomide as precipitating factor of renal failure in a patient with relapsing-remitting multiple sclerosis and focal segmental glomerulosclerosis","volume":"46","author":"Dattola","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"2026012001321329000_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277 28002679","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012001321329000_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468 28002688","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012001321329000_CR9","doi-asserted-by":"publisher","first-page":"102381","DOI":"10.1016\/j.msard.2020.102381 32653735","article-title":"Acute pancreatitis after Ocrelizumab treatment for relapsing remitting multiple sclerosis","volume":"45","author":"Adamec","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"2026012001321329000_CR10","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/ibd\/izaa057 32198886","article-title":"First case of refractory colitis caused by ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026012001321329000_CR11","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.msard.2019.101866 31821962","article-title":"Two cases of Meningitis associated with Ocrelizumab therapy","volume":"38","author":"Theriault","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2026012001321329000_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044 30844611","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2026012001321329000_CR13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191 34094516","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2020","journal-title":"Clin Kidney J"},{"issue":"10","key":"2026012001321329000_CR14","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1097\/TP.0000000000002352 29965953","article-title":"Efficient B cell depletion with rituximab despite massive proteinuria","volume":"102","author":"Halfon","year":"2018","journal-title":"Transplantation"},{"key":"2026012001321329000_CR15","doi-asserted-by":"publisher","first-page":"586012","DOI":"10.3389\/fimmu.2020.586012 33628202","article-title":"Rituximab induces complete remission of proteinuria in a patient with minimal change disease and no detectable B cells","volume":"11","author":"Webend\u00f6rfer","year":"2021","journal-title":"Front Immunol"},{"issue":"77","key":"2026012001321329000_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40265-017-0757-6","article-title":"Ocrelizumab: first global approval","volume":"2017","author":"Frampton","year":"2017","journal-title":"Drug"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01504-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01504-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/3\/659\/66016193\/joneph_36_3_1504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01504-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/3\/659\/66016193\/joneph_36_3_1504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:32:19Z","timestamp":1768890739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/3\/659\/8304763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01504-9","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This material is the authors\u2019 own original work, which has not been previously published elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}